This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Life Sciences Accounting & Reporting Congress
March 2025
Philadelphia, PA

Justin Renz
Chief Financial Officer at Ardelyx


Justin has served as Chief Financial & Operations Officer of Ardelyx since January 2023. Before that, Justin had served as our Chief Financial Officer since June 2020. Justin brings over 25 years of experience in the biopharmaceutical industry, with an extensive array of financial and operational experience.

Prior to Ardelyx, Justin served as the president and chief financial officer of Correvio Pharma, a global specialty pharmaceutical company dedicated to the commercialization of cardiovascular and infectious disease products, where he led the sale of the company to ADVANZ PHARMA in May 2020. Prior to Correvio, Justin was executive vice president, chief financial officer and treasurer of Karyopharm Pharmaceuticals, where he led core business and finance functions and multiple financings. Before Karyopharm, Justin was executive vice president and chief financial officer at Zalicus Inc., formerly CombinatoRx, Inc., which he joined in September 2006. At Zalicus, Justion oversaw multiple rounds of equity and debt financings, led the company’s asset monetization strategy and was instrumental in the reverse merger and sale of the company to Epirus Biopharmaceuticals in July 2014. Earlier in his career, Justin held numerous positions of increasing responsibility at EMD Serono Inc., ArQule, Inc., Coley Pharmaceutical Group, Millipore Corporation and Arthur Andersen LLP. He received a Bachelor of Arts in Economics and Accounting from the College of the Holy Cross, a Master of Science in Taxation from Northeastern University and a Master of Business Administration from Suffolk University.

Agenda Sessions

  • Insights from the CFO